Co-Diagnostics announced that it welcomes Ivory Chang as the company’s Chief Regulatory Affairs Officer. “Ms. Chang’s in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CODX:
- Co-Diagnostics price target lowered to $2 from $3 at H.C. Wainwright
- Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results
- Co-Diagnostics awarded grants by the Bill & Melinda Gates Foundation
- Co-Diagnostics awarded $1.2M in funding from NIH for Co-Dx PCR Home platform
- Co-Diagnostics settles with SEC over charges of ‘misleading’ releases
